TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18798830
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) intravenous (i.v.)
Study: 18798830
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) intravenous (i.v.)
Study: 15849424
Drug: Apple polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple polyphenol (Ap) 500 mg once daily for 12 weeks
Study: 7745785
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia plus epidural anesthesia (bupivacaine 0.25% with 200,000 epinephrine, 0.75 ml.kg‐1)
Study: 7010929
Drug: Gemfibrozil (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (1200 mg daily for 3 months)
Study: 31479722
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg subcutaneously, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Study: 31479722
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered in-hospital and after 4 weeks, on top of atorvastatin 40 mg.
Study: 15073451
Drug: Rosuvastatin (Crestor)
Normalized name: rosuvastatin Oral Tablet [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin (Crestor) 5-40 mg
Study: 11284474
Drug: Current protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current protocol (gastric residual volume threshold, 150 mL, optional prokinetic)
Study: 11284474
Drug: Proposed feeding
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed feeding protocol (gastric residual volume threshold 250 mL, mandatory prokinetic)
Study: 3548735
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplement (MaxEPA)
Study: 12712108
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg (twice daily)
Study: 12712108
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg (twice daily)
Study: 12712108
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg (twice daily)
Study: 8160602
Drug: Mexiletine (720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (720 mg/day)
Study: 27670863
Drug: Therapeutic aerobic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic aerobic exercise with music therapy (G1)
Study: 25447467
Drug: Tobacco Tactics
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco Tactics website with nurse counseling by phone and access to nicotine replacement therapy (NRT)
Study: 20668455
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day; n=15)
Study: 17436360
Drug: Xiong‐gui‐tiao‐xue‐yin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiong‐gui‐tiao‐xue‐yin at a dose of 6.0 g/day (Group X)
Study: 15464183
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy (n=200)
Study: 15464183
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (n=210)
Study: 8003844
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (APD) 30 mg as a single infusion every 3 months
Study: 8003844
Drug: Oral fluoride
Normalized name: sodium fluoride Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluoride (20‐30 mg F/day)
Study: 2571403
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) aqueous nasal spray
Study: 28880972
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MVA-5T4 and cyclophosphamide
Study: 17094524
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg cisatracurium [2ED95]
Study: 17094524
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg rocuronium [2ED95]
Study: 17094524
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.075 mg/kg cisatracurium [1ED95] plus 0.3 mg rocuronium [1ED95]
Study: 9921571
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of 1.6 ml (480 mcg) of G-CSF
Study: 9921571
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of 0.8 ml each of G-CSF
Study: 3310318
Drug: Metformin (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.7 g/day)
Study: 574098
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Metformin + Clofibrate)
Study: 31735410
Drug: Acute-phase cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute-phase cognitive therapy (A-CT)
Study: 31735410
Drug: Continuation-phase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation-phase treatment (CCT)
Study: 31735410
Drug: Matched pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched pill placebo
Study: 31153781
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (HC) 100mg every eight hours until the second postoperative day
Study: 23363495
Drug: Fractional dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dose of IPV (one fifth of a full dose) administered intradermally
Study: 23363495
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of IPV administered intramuscularly
Study: 9447478
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day for 3 days)
Study: 11476796
Drug: Subcutaneous hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hCG (5,000 IU)
Study: 11476796
Drug: Intramuscular hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hCG (5,000 IU)
Study: 11476796
Drug: Both subcutaneous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both subcutaneous and intramuscular hCG
Study: 9570254
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (750 mg b.d.)
Study: 9570254
Drug: Intravenous cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cephazolin (1 g b.d.)
Study: 27836205
Drug: Standard skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard skin preparation without CMS
Study: 22956434
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (TAC) plus prednisone for 12 months
Study: 22956434
Drug: Prednisone combined
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone combined with intravenous cyclophosphamide (CYC) for 24 weeks
Study: 22956434
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (TAC) plus prednisone
Study: 19700774
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral enoximone
Study: 17145722
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily (Amlodipine-based regimen)
Study: 17145722
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg daily (Atenolol-based regimen)
Study: 15307550
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated circuit and oxygenator (group H)
Study: 9060560
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) filgrastim; 5 microg/kg/d
Study: 3776949
Drug: 20% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% ethanol (6 ml)
Study: 3776949
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (20 mg/kg iv)
Study: 24642785
Drug: High-calcium (CAL)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium (CAL) supplementation (1400 mg of calcium)
Study: 24642785
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) supplementation (400 mg of calcium)
Study: 20516658
Drug: Low-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose beta-carotene (30 mg/day)
Study: 20516658
Drug: High-dose beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta-carotene (90 mg/day)
Study: 18541125
Drug: Maxacalcitol lotion
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxacalcitol lotion
Study: 15825531
Drug: TPD ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPD ophthalmic solution (0.5% tropicamide, 0.5% phenylephrine, 0.1% diclofenac)
Study: 15825531
Drug: Individual solutions
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual solutions (0.5% tropicamide/0.5% phenylephrine, 5% phenylephrine, 0.1% diclofenac)
Study: 15825531
Drug: TPD ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPD ophthalmic solution
Study: 9463561
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (10 mg per day)
Study: 7944840
Drug: Inappropriate medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate medication use
Study: 7944840
Drug: Subjects using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects using three or more prescription drugs
Study: 3295625
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human recombinant interferon-alpha-2c (Hr-IFn alpha 2c) at 1.2 X 10(6) IU/m2 for 28 days, subcutaneously (s.c.)
Study: 3295625
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose treatment of Hr IFn-2c at 1.2 X 10(5) IU/m2, s.c. daily increasing to a well-tolerated dose
Study: 31777234
Drug: Cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (50 mg/time, 2 times/d) and Epalrestat (50 mg/time, 3 times/d)
Study: 29121625
Drug: Face-to-face delivery
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face delivery of the Green Prescription
Study: 22152723
Drug: Canakinumab 150
Normalized name: canakinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg subcutaneously at 8-week intervals
Study: 16502769
Drug: Ramipril test
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril test formulation from Laboratórios Biosintética Ltda (5 mg)
Study: 16502769
Drug: Triatec formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triatec formulation from Aventis Pharma (5 mg)
Study: 15208585
Drug: Albuterol metered‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol metered‐dose inhalers (16 cumulative puffs, doubled at 15-minute intervals)
Study: 11085051
Drug: HRT +
Normalized name: Hormone Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT + K (TTS natural estrogens 50 micrograms/day with progestin and Kava‐Kava extract at a dose of 100 mg, n=13)
Study: 11085051
Drug: ERT +
Normalized name: Enzyme Replacement Therapy Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERT + K (TTS natural estrogens 50 micrograms/day and Kava‐Kava extract at a dose of 100 mg, n=11)
Study: 7689778
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of alkylating agents
Study: 31649304
Drug: Psilocybin (315
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (315 μg/kg PO)
Study: 28541926
Drug: Statin +
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin + omega-3 PUFA 2.52 g/day
Study: 28541926
Drug: Statin +
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Statin + omega-3 PUFA 2.52 g/day + CoQ10 200 mg/day
Study: 28541926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unaltered statin therapy)
Study: 24348043
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E tocotrienol-rich fraction (TRF) 180 mg tocotrienols, 40 mg tocopherols
Study: 24348043
Drug: Placebo (0.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.48 mg tocotrienols, 0.88 mg tocopherols)
Study: 21513530
Drug: School-based lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based lifestyle intervention programme including weekly lifestyle-lessons for children, teacher training, and parent training.
Study: 16942618
Drug: Candesartan/HCTZ (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan/HCTZ (16 mg/12.5 mg) with passive compliance monitoring (Group B)
Study: 16942618
Drug: Candesartan/HCTZ (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan/HCTZ (16 mg/12.5 mg) with DRC intervention program (Group C)
Study: 16942618
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Group A)
Study: 10861338
Drug: L-Carnitine (L-C)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Carnitine (L-C) 2 g twice daily for 8 weeks
Study: 10861338
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose) 2 g twice daily for 8 weeks
Study: 9182742
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + 2% minocycline gel (S&Mi)
Study: 9182742
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing + 25% metronidazole gel (S&Me)
Study: 2422004
Drug: Org 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2766 (synthetic ACTH4-9 analog), 40 mg daily for 6 months
Study: 30212849
Drug: Abstinence-optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinence-optimized treatment (A-OT): 3 weeks of prequit mini-lozenges, 26 weeks of nicotine patch + mini-lozenges, three in-person and eight phone counseling sessions, and 7-11 automated calls to prompt medication use
Study: 30212849
Drug: Recommended usual
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended usual care (R-UC): 10 min of in-person counseling, 8 weeks of nicotine patch, and referral to quitline services
Study: 27958384
Drug: EUS-guided ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUS-guided ethanol injection (n=10)
Study: 23856100
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day of oral olanzapine
Study: 22800696
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao capsules (2 g/d) for 28 days after operation
Study: 22800696
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (2 g/d) for 28 days after operation
Study: 11719594
Drug: HLA-G*0104 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA-G*0104 or HLA-G*0105N allele presence
Study: 18692637
Drug: Esmolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (all doses)
Study: 3300711
Drug: Postoperative CMF
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative CMF chemotherapy
Study: 3300711
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (Control)
Study: 10079452
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (bupivacaine 0.75%)
Study: 7573090
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg hs (average dose 29.5 mg)
Study: 2076392
Drug: Nifedipine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (80 mg per day)
Study: 30601990
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear (CH) treatment in early group (EG)
Study: 30601990
Drug: Cervical headgear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical headgear (CH) treatment in late group (LG)
Study: 21063868
Drug: Red Bull®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Bull® Energy Drink (250 ml)
Study: 9645979
Drug: 619C89 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 619C89 (up to 2.5 mg/kg loading plus 1.25 mg/kg/8 h maintenance)
Study: 9645979
Drug: 619C89 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 619C89 (doses below 2 mg/kg + 1 mg/kg/8 h)
Study: 9645979
Drug: 619C89 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 619C89 (2 mg/kg/8 h or more)
Study: 7907174
Drug: Zidovudine and
Normalized name: zidovudine and lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine and didanosine combination therapy
Study: 362874
Drug: phenylpropanolamine/aromatic oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylpropanolamine/aromatic oil syrup
Study: 362874
Drug: phenylpropanolamine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylpropanolamine syrup
Study: 362874
Drug: aromatic oil
Normalized name: AROMATIC OILS
Approvals — FDA: no, EMA: no, PMDA: no
Description: aromatic oil syrup
Study: 362874
Drug: placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo syrup
Study: 26267983
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg taken orally 30 minutes before endometrial biopsy
Study: 20530522
Drug: Prasterone (DHEA)
Normalized name: prasterone (DHEA)
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prasterone (DHEA) 200 mg/day
Study: 16181530
Drug: Yufeining pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yufeining pills taken orally for half a year
Study: 12708207
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 microgram.Kg‐1) and Midazolam (0.02 mg.Kg‐1)
Study: 8696067
Drug: Non-insulin dependent
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-insulin dependent diabetes mellitus prevalence
Study: 1997425
Drug: Oral immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunization with Salmonella typhi Ty21a
Study: 1997425
Drug: Parenteral administration
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral administration of heat‐killed typhoid vaccine
Study: 22072430
Drug: Ulimorelin 480
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulimorelin 480 μg/kg
Study: 18160764
Drug: Catechin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechin (500 mg: equivalent to 6 or 7 cups of green tea)
Study: 16968503
Drug: Clarithromycin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, amoxicillin, esomeprazole (Group A)
Study: 1348405
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg cetirizine
Study: 23390092
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood progenitor cell therapy
Study: 21393394
Drug: Heparin (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (unfractionated or low molecular weight [enoxaparin])
Study: 21393394
Drug: Heparin-treated patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-treated patients (ELISA positive but platelet-activating antibody negative)
Study: 21393394
Drug: Heparin-treated antibody-negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-treated antibody-negative control subjects
Study: 19716489
Drug: Morphine-based postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-based postoperative PCA with preoperative anxiolytics prescribed
Study: 19716489
Drug: Morphine-based postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-based postoperative PCA without preoperative anxiolytics prescribed
Study: 19716489
Drug: Morphine-based postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-based postoperative PCA
Study: 11478826
Drug: Enteral formula
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral formula supplemented with 22 g/l partially hydrolyzed guar (soluble fiber)
Study: 8555550
Drug: Constant ultrafiltration
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant ultrafiltration with constant dialysate Na of 140 mEq/L (Group A)
Study: 8555550
Drug: Sequentially decreasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequentially decreasing ultrafiltration with sequentially decreasing dialysate Na from 150 to 140 mEq/L (Group C)
Study: 3310843
Drug: Baked rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked rice (90 g, raw, cooked for 10 min at 160 degrees C after boiling)